Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6677MR)

This product GTTS-WQ6677MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6677MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3451MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ9870MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ14960MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ15738MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ6957MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ656MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ14598MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ6999MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW